Leadership Team

Great Minds Think Differently

With a collective wealth of industry success, knowledge and drive, our leaders share a passion for reinvigorating healthcare.

  • Scott Tarriff
    Chief Executive Officer, Board Member, Executive Committee

    Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief

  • David Pernock
    President and Chief Commercial Officer

    David has been our President and Chief Commercial Officer since January 2017.David brings a wealth of pharmaceutical and biotechnology experience to the Eagle leadership team, having previously served as a member of the board from April 2015 through December 2016. David’s strategic focus and entrepreneurial spirit has contributed to the commercial success of many products throughout his distinguished career.

    Before joining Eagle, David served as Chairman of the board of directors and CEO (2010-

  • Pete A. Meyers
    Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

    Pete joined Eagle in May 2017 with more than 2 decades of experience in the healthcare industry. From 2016 to 2017, he served as Chief Financial Officer of Motif BioSciences, Inc. Prior to joining Motif, Pete spent 3 years as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation.

    Pete has 18 years of experience as a healthcare investment banker, including Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc.  Pete currently serves on

  • Adrian Hepner, MD, PhD
    Executive Vice President and Chief Medical Officer

    Adrian has over 25 years of experience in US and international clinical research and drug development.  He has been our Chief Medical Officer since January 2015. His experience includes the development and implementation of the clinical and regulatory strategies for a multiple number of products from early-stage development through successful New Drug Application (NDA) and EU regulatory filings.

  • Daniel O'Connor
    Executive Vice President, Biologics and Corporate Development

    Dan is our Executive Vice President of Biologics and Corporate Development.  Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure.

Business Wire InvestorHQsm